Search results for "trials"

showing 10 items of 966 documents

GINA 2019: a fundamental change in asthma management

2019

GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.http://bit.ly/310LLzE

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescentMild asthmaGlobal HealthAsthma managementAdministration InhalationHumansMedicineAnti-Asthmatic AgentsDisease management (health)Monitoring PhysiologicRandomized Controlled Trials as TopicAsthmaInhalationbusiness.industryInhalerDisease Managementmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesBudesonide/formoterolPractice Guidelines as TopicFundamental changebusinessmedicine.drugEuropean Respiratory Journal
researchProduct

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the lit…

2018

This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults. It is based on a systematic literature search conducted in MEDLINE, Embase and the Cochrane Library to identify relevant studies. After a short overview of severe asthma and its treatment we present studies showing a dose–response relationship in asthmatic patients treated with OCS and then consider by organ systems the undesired effects demonstrated in clinical and epidemiological studies in patients with OCS-dependent asthma. It was found that the risk of developing various OCS-related complications, including infections, diabetes …

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaOsteoporosisMEDLINEAdministration OralCochrane Library03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesDiabetes mellitusHealth careEpidemiologymedicineHumans030212 general & internal medicineIntensive care medicineRandomized Controlled Trials as TopicAsthmaDose-Response Relationship Drugbusiness.industrymedicine.diseaseAsthma030228 respiratory systembusinessEuropean Respiratory Journal
researchProduct

Immunologic diseases and brain tumors

2010

To do a bibliographic review of the given association of atopic [AD] and immunological diseases with central nerve system tumors [CNST] described a few years ago and to know the knowledge available. It gives an overview of the studies describing this association, and those explaining its mechanism. A negative association of AD with CNST stands out in case-control studies, which is not observed in cohort studies. The greatest association is seen for gliomas and is less significant for meningiomas. A clearer definition for the AD under study, tumour types, and the exact biochemical and clinical parameters to help diagnoses are the recommended as well as to establish an aetiologic and temporal…

AdultRiskPathologymedicine.medical_specialtyImmunologyMEDLINENegative associationBioinformaticsCohort StudiesImmunologic diseasesImmunology and AllergyMedicineAnimalsHumansChildPharmacologyClinical Trials as Topicbusiness.industryMechanism (biology)Brain NeoplasmsCase-control studyImmunityGeneral MedicineUnited StatesEuropeImmune System DiseasesCase-Control StudiesImmunological diseasesCentral nerve systembusinessCohort study
researchProduct

Group treatment for substance use disorder in adults: A systematic review and meta-analysis of randomized-controlled trials

2019

Abstract Background and aims From residential programs to outpatient services, group therapy permeates the clinical field of substance misuse. While several group interventions for substance use disorders (SUDs) have demonstrated effectiveness, the existing evidence on group therapy has not been systematically reviewed. The current meta-analysis aims to provide estimates of the efficacy of group therapy for SUDs in adults using rigorous methods. Methods We included studies comparing group psychotherapy to no treatment control groups, individual psychotherapy, medication, self-help groups, and other active treatments applying no specific psychotherapeutic techniques for patients with substan…

AdultSubstance-Related Disordersmedicine.medical_treatmentmedia_common.quotation_subjectPsychological intervention030508 substance abuseMedicine (miscellaneous)AnxietySubstance use disorderlaw.inventionGroup psychotherapy03 medical and health sciences0302 clinical medicineRandomized controlled trialGroup psychotherapylawSettore M-PSI/07 - Psicologia DinamicamedicineHumans030212 general & internal medicineRandomized Controlled Trials as Topicmedia_commonAbstinenceDepressionbusiness.industryAbstinencemedicine.diseaseDrug AbstinenceSubstance abuseSelf-Help GroupsMeta-analysisPsychiatry and Mental healthClinical PsychologyMeta-analysisPsychotherapy GroupSystematic reviewAnxietyPshychiatric Mental Healthmedicine.symptom0305 other medical sciencebusinessClinical psychologyJournal of Substance Abuse Treatment
researchProduct

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

2003

The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrixtrade mark) has been shown to induce a strong booster response to all the vaccine components in 4-6 year olds. However, anti-diphtheria antibody levels were observed to be lower when compared to the "full strength" paediatric DTPa vaccine. To assess the impact of this difference on long-term protection, a mathematical model was developed to predict diphtheria antibody decay over time. The model was based on a linear decrease in log-transformed antibody concentrations after the first year post-vaccination. When applied to data collected 3.5 years after vaccination of 4-6 year olds with either DTPa or dTpa, …

AdultTime Factorsanimal diseasesImmunization SecondaryModels Biologicalcomplex mixturesCohort StudiesAntigenmedicineHumansChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleRandomized Controlled Trials as TopicBooster (rocketry)General VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaVaccinationPublic Health Environmental and Occupational HealthDiphtheriarespiratory systemmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationChild PreschoolImmunologycardiovascular systembiology.proteinMolecular MedicineAntibodybusinessDiphtheria antibodycirculatory and respiratory physiologyVaccine
researchProduct

Analysis of Safety and Tolerability Data Obtained from Over 1,500 Patients Receiving Topiramate for Migraine Prevention in Controlled Trials

2008

Objective.  Topiramate is an effective and generally well-tolerated migraine preventive therapy, as shown in three large, randomized, double-blind, placebo-controlled registration trials. Based upon efficacy/tolerability, topiramate 100 mg/day (50 mg BID) is the recommended target dose for most patients with migraine. To further assess the safety and tolerability of topiramate for migraine prevention, we analyzed safety data from 1,580 patients who participated in the three pivotal registration trials or an earlier pilot, randomized, double-blind, placebo-controlled trial. Methods.  The safety population consisted of all patients who took ≥1 dose of study medication during the double-blind …

AdultTopiramateAdolescentNauseaMigraine DisordersPopulationPhysical examinationFructosePlaceboTopiramatemedicineHumansChildAdverse effecteducationAgedRandomized Controlled Trials as Topiceducation.field_of_studymedicine.diagnostic_testbusiness.industryPatient SelectionDrug ToleranceGeneral MedicineMiddle Agedmedicine.diseaseNeuroprotective AgentsAnesthesiology and Pain MedicineTolerabilityMigraineAnesthesiaNeurology (clinical)Safetymedicine.symptombusinessmedicine.drugPain Medicine
researchProduct

Types of Adult Attention-Deficit/Hyperactivity Disorder: A Replication Analysis.

2019

OBJECTIVE Research supports the importance of emotional symptoms in adults with attention-deficit/hyperactivity disorder (ADHD), which are not reflected in the DSM-5 or ICD-10 criteria. The Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) assesses these symptoms, plus inattention, hyperactivity, and impulsivity. This scale allowed us to divide adult ADHD into 2 subtypes in a 2015 publication: ADHD inattentive presentation and ADHD emotional dysregulation presentation. The present study refines this observation using a larger, more diverse sample. METHODS Eight double-blind adult ADHD clinical trials (encompassing 1,490 subjects) were selected because they included assessment…

AdultTreatment responseImpulsivityFactor structurebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineRating scalemental disordersMedicineAttention deficit hyperactivity disorderHumansAffective SymptomsClinical Trials as Topicbusiness.industryAttention deficit disordermedicine.diseaseEmotional dysregulation030227 psychiatryClinical trialPsychiatry and Mental healthAttention Deficit Disorder with Hyperactivitymedicine.symptombusinessFactor Analysis Statistical030217 neurology & neurosurgeryClinical psychologyThe Journal of clinical psychiatry
researchProduct

Evidence of bias in randomized clinical trials of hepatitis C interferon therapies

2017

Introduction: Bias may occur in randomized clinical trials in favor of the new experimental treatment because of unblinded assessment of subjective endpoints or wish bias. Using results from published trials, we analyzed and compared the treatment effect of hepatitis C antiviral interferon therapies experimental or control. Methods: Meta-regression of trials enrolling naïve hepatitis C virus patients that underwent four therapies including interferon alone or plus ribavirin during past years. The outcome measure was the sustained response evaluated by transaminases and/or hepatitis C virus-RNA serum load. Data on the outcome across therapies were collected according to the assigned arm (exp…

Adultmedicine.medical_specialtyAlternative medicineAntiviral Agentslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialBiaslawInterferonInternal medicinemedicineHumans030212 general & internal medicineSettore SECS-S/05 - Statistica SocialeRandomized Controlled Trials as TopicPharmacologyObserver Variationbusiness.industryGeneral MedicineHepatitis CMiddle Agedmedicine.diseaseHepatitis Cinterferon randomized controlled trials bias trial design favore armTreatment OutcomeResearch Design030220 oncology & carcinogenesisCase-Control StudiesPhysical therapyInterferonsbusinessmedicine.drug
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct